Dr. Milner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14690 Manuella Rd
Los Altos Hills, CA 94022Phone+1 650-941-7807
Education & Training
University of Virginia Medical CenterFellowship, Cardiovascular Disease, 1984 - 1986
Johns Hopkins UniversityResidency, Internal Medicine, 1981 - 1984
Univ Liverpool- Fac MedClass of 1980
Certifications & Licensure
MO State Medical License 1987 - 2025
MD State Medical License 1987 - 1987- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy Start of enrollment: 2018 Nov 05
- Natural History of Infantile Neuroaxonal Dystrophy Start of enrollment: 2018 Jul 30
- A Natural History Study of Infantile Neuroaxonal Dystrophy Start of enrollment: 2019 Jun 17
Publications & Presentations
PubMed
- 20 citationsA randomized trial of budiodarone in paroxysmal atrial fibrillationMichael D. Ezekowitz, Rangadham Nagarakanti, Andrzej Lubiński, Olga Bandman, Daniel M. Canafax
Journal of Interventional Cardiac Electrophysiology. 2012-06-01 - 21 citationsTecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy part...Linda M. Bavisotto, David J. Ellis, Peter G. Milner, Daniel Combs, Ian Irwin
Journal of Clinical Pharmacology. 2011-04-01 - 190 citationsA novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence.Peter G. Milner, Yue-Sheng Li, Ruth M. Hoffman, Charles M. Kodner, Ned R. Siegel
Biochemical and Biophysical Research Communications. 1989-12-30
Press Mentions
Renexxion Ireland Ltd. And Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of Naronapride in Patients with GastroparesisFebruary 15th, 2023- Renexxion Ireland Ltd. And Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of Naronapride in Patients with GastroparesisFebruary 15th, 2023
- Renexxion Seeks FDA OK to Test Naronapride for GI Problems in CFJanuary 11th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
